KOSDAQBiotech & Pharma365270

curacle

₩7,370▼ 3.41%2026-11-18 close
Market Cap
₩163.3B
Turnover
₩500M
Volume
60K
Shares out.
22.2M
PER
—
PBR
2.9×
EPS
-₩460
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Licensing Revival, Losses Still Weigh

curacle regained a licensing deal in 2026, but its disclosed results show an operating loss and a net loss attributable to controlling shareholders in every year from 2022 to 2025.

  1. 1

    In May 2026 curacle signed an MT-103 licensing deal worth up to USD 1,077.75 million, and the upfront of about KRW 5.8 billion was disclosed on June 5, 2026.

  2. 2

    Disclosed revenue peaked at KRW 10.3 billion in 2023 and then fell to KRW 1.63 billion in 2024 and KRW 7.1 million in 2025.

  3. 3

    Operating profit of KRW 2.36 billion in Q2 2026 turned into an operating loss of KRW 2.67 billion in Q3 2026.

  4. 4

    In a Phase 2b trial, CU01 reduced uACR by 21% to 22% versus placebo, and the company plans to pursue Phase 3 entry.

  5. 5

    Total equity was KRW 37.1 billion at the end of 2025, and the debt ratio fell from 97.9% in 2024 to 43.5% in 2025.

02

Business structure

curacle is a biopharmaceutical company developing drugs aimed at endothelial dysfunction blockers. Its small-molecule platform SOLVADYS and antibody platform EAGLES underpin a pipeline spanning kidney, retinal, vascular and brain diseases.

An independent research firm, ARIS, said in March 2026 that curacle held 16 pipeline assets. CU01 completed a Phase 2b trial in 240 patients across 24 university hospitals in Korea, and at 24 weeks uACR fell 21.45% and 22.21% versus the control group.

CU06 (Rivastherat), an oral drug for diabetic macular edema, is preparing to enter a Phase 2b trial in the United States. On the antibody side, the key assets are the Tie2-activating antibodies MT-101 and MT-103, co-developed with Mabtics.

MT-103 was licensed to Memento Medicines in May 2026, and licensing revenue is shared 50:50 with the partner. curacle completed a merger with a raw-material pharmaceutical company in early 2026. Revenue is highly sensitive to whether a licensing deal is signed.

After the rights to CU06 were returned in 2024 by a French ophthalmology company, the deal that was effectively curacle's only prior licensing success lost effect, and disclosed revenue fell to KRW 1.63 billion in 2024 and KRW 7.1 million in 2025.

Licensing talks for CU01 in Korea are under way with several pharmaceutical companies. In the retinal market, injectables such as Eylea and Vabysmo lead.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3—-₩2.9B—
2025Q4₩0-₩4.7B—
2026Q1₩1B-₩3B−285.9%
2026Q2₩7.2B₩2.4B32.8%
2026Q3₩900M-₩2.7B−300.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩3.6B-₩12B-₩11.4B−334.4%−24.7%20.5%
2023₩10.3B-₩10.5B-₩11.6B−102.1%−27.7%66.7%
2024₩1.6B-₩12.6B-₩14.9B−773.9%−49.7%97.9%
2025₩7,101,468-₩16.5B-₩18.1B−232393.8%−48.8%43.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On the disclosed annual figures, revenue rose from KRW 3.58 billion in 2022 to KRW 10.3 billion in 2023, an increase of 187.3% that made 2023 the largest year in the 2022 to 2025 period.

Revenue then fell to KRW 1.63 billion in 2024, down 84.1%, and to KRW 7.1 million in 2025, down 99.6%, so it declined for two consecutive years after the 2023 peak, and 2025 was the smallest year.

Operating losses were KRW 12 billion in 2022, KRW 10.5 billion in 2023, KRW 12.6 billion in 2024 and KRW 16.5 billion in 2025, a loss in each of the four years. The loss narrowed in 2023 but widened again in 2024 and 2025.

Net losses attributable to controlling shareholders widened from KRW 11.4 billion in 2022 to KRW 11.6 billion in 2023, KRW 14.9 billion in 2024 and KRW 18.1 billion in 2025. Net loss including non-controlling interests was disclosed at the same amounts.

The operating margin was -334.4% in 2022, -102.1% in 2023, -773.9% in 2024 and -232,393.8% in 2025, and the 2025 figure is extreme because revenue of KRW 7.1 million makes the denominator very small, so it should be read alongside the absolute loss.

Operating cash outflow was KRW 11.2 billion in 2022, KRW 9.39 billion in 2023, KRW 9.51 billion in 2024 and KRW 13.4 billion in 2025, the largest outflow of the four years. The debt ratio rose from 20.5% in 2022 to 97.9% in 2024 and fell to 43.5% in 2025.

On a quarterly basis, Q1 2026 revenue was KRW 1.05 billion with an operating loss of KRW 3 billion. Q2 2026 revenue was KRW 7.18 billion, up 584.9% from the prior quarter, with operating profit of KRW 2.36 billion, a swing to profit.

Q3 2026 revenue was KRW 891 million, down 87.6% from the prior quarter, with an operating loss of KRW 2.67 billion. The Q2 profit falls in the same quarter as the upfront receipt disclosed in June, so whether the revenue was one-off in nature should be checked against the periodic report.

The net loss attributable to controlling shareholders over the last four quarters totaled KRW 7.45 billion. In the 2025 rights offering, the company had projected Q1 2026 revenue of KRW 1.667 billion and Q2 2026 revenue of KRW 2.5 billion, while disclosed revenue was KRW 1.05 billion in Q1 and KRW 7.18 billion in Q2.

05

Industry analysis

In retinal disease, the front-line market is led by injectables such as Eylea and Vabysmo, and the burden of repeated eye injections remains. curacle positions CU06 as an oral alternative.

In kidney disease, many patients still do not see enough reduction in proteinuria on standard treatments such as RAAS inhibitors and SGLT-2 inhibitors, and the need for new therapies is considered relatively large. curacle said CU01 reduced uACR by up to 35.20% in patients taking standard therapy, as reported after a presentation in October 2026.

In licensing, the NewCo model has emerged as a new commercialization approach. Memento, the counterparty to MT-103, is a US biotech set up in the NewCo format for this deal, and after the license it raised USD 93 million from investors including RA Capital and Sanofi Ventures.

Disclosure about the counterparty's founding date, investors and management is limited, which remains a concern for the market.

Compared directly with other listed Korean biopharma companies, curacle has small revenue and a pipeline concentrated at the Phase 2b stage, so a single licensing deal can drive its overall results. This means the timing at which clinical-stage assets translate into reported earnings remains uncertain.

06

Outlook

The company has outlined three main paths ahead. First, it plans to pursue Phase 3 entry for CU01 and is in talks with several pharmaceutical companies on a licensing deal for the Korean rights.

Second, for CU06 it has signed a contract with a global CRO for a Phase 2b trial and, after a meeting with the US FDA, said in March 2026 that it planned to file an IND application during 2026, with completion of Phase 2b trial drug manufacturing also reported around that time.

Third, MT-101, co-developed with Mabtics, is under discussion for global collaboration. Under the MT-103 deal, milestones of about KRW 59.6 billion are payable at each stage from clinical success through global regulatory approval.

The company said the upfront can be received at a timing similar to typical licensing deals. A curacle official said confidential contract terms cannot be disclosed voluntarily, and that more information can be provided once Memento starts public promotion.

The annual business report is filed after year-end, and the report for fiscal 2025 was filed on March 18, 2026. The next checkpoint is therefore how much licensing income is reflected in annual revenue in the fiscal 2026 business report. Whether the CU01 licensing deal is concluded is another variable that could change the revenue structure.

07

Valuation

PER
—
PBR
2.9×
ROE
-17.9%
EPS
-₩460
BPS
₩2,724
Dividend per share
₩0

The price-to-book ratio sits above 1 times, meaning the share price carries a premium over net assets. Total equity was KRW 37.1 billion at the end of 2025, all of it attributable to controlling shareholders.

Because the last four quarters show net losses attributable to controlling shareholders, the price-to-earnings ratio cannot be calculated. The dividend yield is below the industry average. Industry commentary points to licensing progress and clinical results as the key variables for enterprise value.

On disclosed figures, one-time receipts such as licensing upfronts can swing quarterly profit, which makes quarterly earnings volatile. A profit in Q2 2026 and a return to an operating loss in Q3 2026 came within the same year.

The debt ratio fell from 97.9% in 2024 to 43.5% in 2025, which indicates lower financial burden. While the loss structure has not been resolved, the share price level reflects how much expectations for deal completion and clinical outcomes are already priced in.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Licensing track record re-established

The MT-103 deal announced in May 2026 is worth up to USD 1,077.75 million, and the June 2026 disclosure confirmed an upfront of about KRW 5.8 billion. Media reports converted the total to KRW 1.5636 trillion to KRW 1.6166 trillion depending on the exchange rate. It is described as the first licensing success in two years since the 2024 rights return.

Phase 2b data and Phase 3 plan

In the Korean Phase 2b trial, CU01 reduced uACR by 21.45% and 22.21% versus placebo, while eGFR tended to be maintained. The company says it will pursue Phase 3 entry on this basis. Licensing talks for the Korean rights are under way with several pharmaceutical companies.

Signs of balance-sheet improvement

The debt ratio fell from 97.9% in 2024 to 43.5% in 2025, and total equity at the end of 2025 was KRW 37.1 billion. Operating profit of KRW 2.36 billion in Q2 2026 marked a swing to profit.

Because revenue was sharply lower in 2025, the quarter in which licensing income is reflected is cited as a factor that could change the earnings trend.

09

Bear factors

Four straight years of losses and a revenue gap

Operating losses were KRW 12 billion, KRW 10.5 billion, KRW 12.6 billion and KRW 16.5 billion from 2022 to 2025, a loss in each year. Disclosed revenue fell to KRW 7.1 million in 2025.

The KRW 16.5 billion operating loss in 2025 was the largest loss in the period, and operating cash outflow of KRW 13.4 billion was also the largest of the four years.

Limited counterparty disclosure and contingent income

Disclosure about Memento, the MT-103 counterparty, including its founding date, investors and management, is limited. Milestones of about KRW 59.6 billion are contingent income paid only after clinical success and regulatory approvals. Income beyond the upfront remains uncertain and will take time to materialize.

Quarterly earnings volatility

Q2 2026 revenue of KRW 7.18 billion and operating profit of KRW 2.36 billion reversed in Q3 2026 to revenue of KRW 891 million and an operating loss of KRW 2.67 billion. Net losses continue to accumulate, and a structure in which quarterly results swing with one-time receipts is cited as a bearish factor.

10

Risk factors

Clinical and regulatory risk

CU01 still needs to enter Phase 3 and CU06 has yet to start its US Phase 2b trial. Positive Phase 2b results do not guarantee Phase 3 success, and schedules could slip depending on regulatory requirements. The 2024 rights return by the French partner shows that partnerships can end before development is completed.

Deal realization risk

The MT-103 headline value is a maximum, and the amount actually received depends on milestones being achieved. Won-denominated figures differ across reports because of exchange-rate assumptions.

Talks on the Korean rights for CU01 are under way with several pharmaceutical companies, but no signed agreement has been disclosed.

Financing risk

Operating losses and operating cash outflows continued for four straight years, with the 2025 outflow at KRW 13.4 billion. During the 2025 rights offering the company said additional funding might be needed if planned revenue did not materialize.

Some reports say the deal largely resolves risk tied to the revenue requirement for the administrative-issue designation, but continued losses remain.

11

What to watch next

  1. Around mid-March 2027 (based on the prior year's report filed March 18, 2026)

    Annual revenue and operating results in the fiscal 2026 business report. How much licensing income is reflected in annual revenue, and the size of the operating loss, are the next checkpoints.

  2. Around mid-May 2027 (based on the Q1 2026 quarterly report filed May 15, 2026)

    Q1 2027 revenue scale and direction of operating results. This shows whether revenue holds up after the upfront-driven spike in Q2 2026.

  3. After December 2026 (disclosure timing undetermined)

    Disclosure of the IND filing and approval and the start of the US Phase 2b trial for CU06. The company had said it planned to file the IND during 2026.

  4. Timing undetermined (company plan stage)

    Signing of a licensing deal for CU01's Korean rights and clearer plans for Phase 3 entry. If a deal is signed, the revenue structure and cash flow could change.

12

Overall view

curacle rebuilt a licensing track record in 2026, with the MT-103 deal in May and the upfront disclosure in June, its first such success in two years.

On disclosed figures, revenue peaked at KRW 10.3 billion in 2023 and fell to KRW 7.1 million in 2025, and operating losses and net losses attributable to controlling shareholders were recorded in each year from 2022 to 2025.

Operating profit of KRW 2.36 billion in Q2 2026 marked a swing to profit, but Q3 2026 returned to an operating loss of KRW 2.67 billion. Key variables in the pipeline remain the CU01 Phase 2b data and planned Phase 3 entry, and CU06's preparation for a US Phase 2b trial.

Bearish factors include limited counterparty disclosure, milestone-based contingent income, and volatile quarterly revenue. On the financial side, total equity of KRW 37.1 billion and a debt ratio of 43.5% at the end of 2025 both improved from 2024.

The next checkpoints are the revenue and licensing income reflected in the fiscal 2026 business report, the start of the CU06 trial, and any disclosure of a CU01 licensing agreement.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. mt.co.kr
  2. news.nate.com
  3. pharmnews.com
  4. eduinfom.com
  5. m.irgo.co.kr
  6. thebionews.net
  7. mt.co.kr
  8. m.news.nate.com
  9. m.news.nate.com
  10. m.thebell.co.kr
  11. curacle.com
  12. etoday.co.kr
  13. news.nate.com
  14. m.news.nate.com
  15. newspim.com
  16. fnnews.com
  17. dailypharm.com
  18. m.news.nate.com

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis